Analysis of E2 gene integrity in HPV16 and HPV58 viruses isolated from women with cervical pathology
AUTOR(ES)
González-Losa, María del R, Puerto-Solis, Marylin, Tenorio Ruiz, Juan, Rosado-López, Ariel I, Hau-Aviles, Oscar, Ayora-Talavera, Guadalupe, Cisneros-Cutz, Isidro, Conde-Ferráez, Laura
FONTE
Mem. Inst. Oswaldo Cruz
DATA DE PUBLICAÇÃO
31/10/2016
RESUMO
Integration of human papillomavirus (HPV) DNA into human cells accompanied by the disruption of the viral genome has been described as a prerequisite for cancer development. This study aimed to investigate E2 gene integrity of HPV16 and HPV58 viruses isolated from infected women with cervical lesions. Forty-two HPV16- and 31 HPV58-positive samples were analysed. E2 integrity was assumed when all fragments covering the E2 gene were amplified with specific polymerase chain reaction primers. Overall, in 59% of the samples, at least one fragment was not amplified in HPV16- (57%) and HPV58-positive samples (61%). Samples from high-grade squamous intraepithelial lesions had the highest frequency of E2 gene disruptions (73%), followed by samples from low-grade squamous intraepithelial lesions (63%) and, finally, samples from invasive cervical cancer (35%). Association between the integrity status of the E2 gene, and lesion grade was assessed by the chi-squared test applied to the combined set of viruses (p = 0.6555) or to populations of the same virus type (HPV58, p = 0.3101; HPV16, p = 0.3024). In conclusion, in this study, no association was found between the presence of E2 gene disruptions and the grade of cervical lesions caused by HPV16 and HPV58.
Documentos Relacionados
- Correlation between ebv co-infection and HPV16 genome integrity in Tunisian cervical cancer patients
- Human papillomavirus type distribution and HPV16 intratype diversity in southern Brazil in women with and without cervical lesions
- The octamer binding site in the HPV16 regulatory region produces opposite effects on gene expression in cervical and non-cervical cells.
- Development of a therapeutic vaccine against HPV16
- Higher prevalence and gene amplification of HPV16 in oropharynx as compared to oral cavity